Sumitomo Pharma America
| Formerly |
|
|---|---|
| Type | Subsidiary |
| Nasdaq: SEPR (1991 - 2009) | |
| Industry | Pharmaceuticals |
| Predecessor |
|
| Founded | 1984 (as Sepracor) |
| Headquarters | Marlborough, Massachusetts, United States |
| Key people | Tsutomu Nakagawa (President and CEO) |
| Products | Latuda Aptiom Kynmobi Lonhala Magnair Lunesta |
| Parent | Sumitomo Pharma |
| Website | https://www.us.sumitomo-pharma.com |
Sumitomo Pharma America Inc. is the American subsidiary of Japanese pharmaceutical company Sumitomo Pharma. It was originally founded in 1984 as Sepracor. In 2010, it was acquired by Sumitomo Dainippon Pharma as a standalone subsidiary and was renamed Sunovion Pharmaceuticals. In 2023, seven Sumitomo subsidiaries were restructured into Sunovion, which was subsequently renamed to Sumitomo Pharma America.
The corporation focuses on therapeutic areas of psychiatry and neurology, oncology, urology, and women's health.